GLYCOPHOS CONCENTRATE FOR SOLUTION FOR INFUSION 216mg/ML

Product Information

Registration Status: Active

GLYCOPHOS CONCENTRATE FOR SOLUTION FOR INFUSION 216mg/ML is approved to be sold in Singapore with effective from 2002-01-04. It is marketed by FRESENIUS KABI (SINGAPORE) PTE LTD, with the registration number of SIN11858P.

This product contains Sodium Glycerophosphate 216mg/ml in the form of INJECTION. It is approved for INTRAVENOUS use.

This product is manufactured by FRESENIUS KABI NORGE AS in NORWAY.

It is an Over-the-counter Medicine that can be freely obtained from any retailer

Sodium Glycerophosphate

Description

Sodium glycerophosphate is one of several glycerophosphate salts. It is used clinically to treat or prevent low phosphate levels [FDA Label]. Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body [A32667]. The extent of this reaction is dependent on the activity of serum alkaline phosphatases.

Indication

Sodium glycerophosphate is indicated for use as a source of phosphate in total parenteral nutrition [FDA Label]. It is used in combination with amino acids, dextrose, lipid emulsions, and other electrolytes.

Mechanism of Action

Sodium glycerophosphate acts as a donor of inorganic phosphate [A32667]. See [DB09413] for a description of phosphate's role in the body.

Pharmacokinetics

Absorption
Peak serum phosphate concentration is reached in 4h [A32667].
Distribution
Metabolism
Glycerophosphate is hydrolyzed to form inorganic phosphate [A32667]. The extent of this reaction is dependent on serum alkaline phosphatase activity.
Elimination

Active Ingredient/Synonyms

Disodium glycerol phosphate | Sodium glycerophosphate anhydrous | Sodium glycerophosphate |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank